Home LiteratureArticle Details
PMID: 24777245 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Getting personal with neoantigen-based therapeutic cancer vaccines.

Cancer immunology research ·Vol. 1 ·No. 1 ·2013-07-00 ·Pages 11-5

Hacohen N, Fritsch EF, Carter TA, Lander ES, Wu CJ

Abstract

Despite years of preclinical efforts and hundreds of clinical studies, therapeutic cancer vaccines with the routine ability to limit or eliminate tumor growth in humans have been elusive. With advances in genome sequencing, it is now possible to identify a new class of tumor-specific antigens derived from mutated proteins that are present only in the tumor. These "neoantigens" should provide highly specific targets for antitumor immunity. Although many challenges remain in producing and testing neoantigen-based vaccines customized for each patient, a neoantigen vaccine offers a promising new approach to induce highly focused antitumor T cells aimed at eradicating cancer cells.

MeSH Terms
Antigens, Neoplasm/immunology Cancer Vaccines/administration & dosage,immunology Humans Neoplasms/immunology,therapy Precision Medicine/methods
Chemicals
Antigens, Neoplasm Cancer Vaccines
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Hacohen Nir
Authors' Affiliations: Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Fritsch Edward F
Carter Todd A
Lander Eric S
Wu Catherine J
References (36)
36 references, click to expand
  1. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
    N Engl J Med. 2012 Jun 28;366(26):2443-54 PMID: 22658127
  2. Expression of tumour-specific antigens underlies cancer immunoediting.
    Nature. 2012 Feb 08;482(7385):405-9 PMID: 22318517
  3. Unique tumor antigens: evidence for immune control of genome integrity and immunogenic targets for T cell-mediated patient-specific immunotherapy.
    Clin Cancer Res. 2006 Sep 1;12(17):5023-32 PMID: 16951217
  4. Epitope landscape in breast and colorectal cancer.
    Cancer Res. 2008 Feb 1;68(3):889-92 PMID: 18245491
  5. Lessons from the cancer genome.
    Cell. 2013 Mar 28;153(1):17-37 PMID: 23540688
  6. Exploiting the mutanome for tumor vaccination.
    Cancer Res. 2012 Mar 1;72(5):1081-91 PMID: 22237626
  7. High frequency of autologous anti-melanoma CTL directed against an antigen generated by a point mutation in a new helicase gene.
    J Immunol. 2000 Jun 1;164(11):6057-66 PMID: 10820291
  8. Applications of next-generation sequencing to blood and marrow transplantation.
    Biol Blood Marrow Transplant. 2012 Jan;18(1 Suppl):S151-60 PMID: 22226099
  9. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses.
    Science. 2008 Sep 26;321(5897):1801-6 PMID: 18772397
  10. The genomic landscapes of human breast and colorectal cancers.
    Science. 2007 Nov 16;318(5853):1108-13 PMID: 17932254
  11. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.
    Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3005-10 PMID: 18287062
  12. A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation.
    Eur J Immunol. 1999 Feb;29(2):592-601 PMID: 10064075
  13. Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens.
    Int J Cancer. 2001 Jul 1;93(1):6-11 PMID: 11391614
  14. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
    N Engl J Med. 2012 Jun 28;366(26):2455-65 PMID: 22658128
  15. Mutated BCR-ABL generates immunogenic T-cell epitopes in CML patients.
    Clin Cancer Res. 2012 Oct 15;18(20):5761-72 PMID: 22912393
  16. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting.
    Nature. 2012 Feb 08;482(7385):400-4 PMID: 22318521
  17. Improved survival with ipilimumab in patients with metastatic melanoma.
    N Engl J Med. 2010 Aug 19;363(8):711-23 PMID: 20525992
  18. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma.
    Science. 1995 Sep 1;269(5228):1281-4 PMID: 7652577
  19. Point mutation in essential genes with loss or mutation of the second allele: relevance to the retention of tumor-specific antigens.
    J Exp Med. 2001 Aug 6;194(3):285-300 PMID: 11489948
  20. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.
    N Engl J Med. 2009 Nov 5;361(19):1838-47 PMID: 19890126
  21. Machine learning competition in immunology - Prediction of HLA class I binding peptides.
    J Immunol Methods. 2011 Nov 30;374(1-2):1-4 PMID: 21986107
  22. A point mutation in the alpha-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma.
    Cancer Res. 2001 May 15;61(10):4078-83 PMID: 11358829
  23. The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68.
    J Exp Med. 1997 Feb 17;185(4):695-705 PMID: 9034148
  24. Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer.
    Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13255-60 PMID: 11687624
  25. High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival.
    Cancer Res. 2001 May 1;61(9):3718-24 PMID: 11325844
  26. Vaccination strategies in follicular lymphoma.
    Curr Hematol Malig Rep. 2009 Oct;4(4):189-95 PMID: 20425407
  27. Prediction of epitopes using neural network based methods.
    J Immunol Methods. 2011 Nov 30;374(1-2):26-34 PMID: 21047511
  28. CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma.
    Nature. 1994 May 5;369(6475):67-71 PMID: 8164742
  29. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens.
    Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):16013-8 PMID: 16247014
  30. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines.
    Nat Rev Cancer. 2008 May;8(5):351-60 PMID: 18418403
  31. Aminopeptidase substrate preference affects HIV epitope presentation and predicts immune escape patterns in HIV-infected individuals.
    J Immunol. 2012 Jun 15;188(12):5924-34 PMID: 22586036
  32. Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia.
    Blood. 2012 Aug 9;120(6):1282-9 PMID: 22592607
  33. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.
    J Clin Oncol. 2010 Nov 1;28(31):4722-9 PMID: 20921459
  34. T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product.
    J Immunol. 2004 May 15;172(10):6057-64 PMID: 15128789
  35. Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides.
    Nat Med. 1995 Nov;1(11):1179-83 PMID: 7584991
  36. Peptidases trimming MHC class I ligands.
    Curr Opin Immunol. 2013 Feb;25(1):90-6 PMID: 23089230
Article Info
Journal
Cancer immunology research
Abbr.
Cancer Immunol Res
ISSN
2326-6074
DOI
10.1158/2326-6066.CIR-13-0022
Published
2013-07-00
Epub
2013-00-07
Pages
11-5
Language
English
Region
United States
NLM ID
101614637
PMCID
PMC4033902
Subset
IM
Grants
NCI NIH HHS · R01 CA155010 · United States
NHLBI NIH HHS · R01 HL103532 · United States
NHLBI NIH HHS · 5 R01 HL103532-03 · United States
NCI NIH HHS · 1R01CA155010-02 · United States
External Links
PubMed source DOI: 10.1158/2326-6066.CIR-13-0022 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2